A Major Breakthrough in Addiction Treatment: Adial Pharmaceuticals Secures a Key Patent. Adial Pharmaceuticals, Inc., a trailblazer in developing therapies aimed at combating addiction and related disorders, has been granted a pivotal patent by the United States Patent and Trademark Office. This development, announced on April 22, 2024, marks a notable milestone in personalized medicine and offers new hope to millions battlin...
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, or AUD, in heavy drinking patients and was recently investigated in the company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotype...
$Adial Pharmaceuticals(ADIL.US)$ thats why it not moving it will go sky rocket According toTipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.9% and a 31.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Lipella Pharmaceuticals, Inc., and SELLAS Life Sciences Group. Currently, the analyst consensus on Adial Pharmaceuticals is a Moderate Buy with an average price t...
1
举报
71306807 :
how often are the " price targets " achieved ?
wwwarrior : this is good